# Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT06977711** · PHASE1 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 10 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Loncastuximab
- **DRUG:** Roflumilast
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT06977711
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-20
- **Primary completion:** 2026-04-15
- **Final completion:** 2026-07-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06977711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06977711, "Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06977711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*